A global fund to speed development of new antibiotics to counter the growing threat of drug-resistant superbugs is likely to need up to $2 billion, the head of a review backed by the British government said on Thursday.
The Science – Business website reports that former Goldman Sachs chief economist Jim O’Neill has urged the establishment of an innovation fund to support research, arguing that far too little is currently invested in hunting for new drugs against drug-resistant infections. “We’ve not yet come up with a number,” O’Neill told an Economist pharmaceuticals conference when asked how big the fund would be. “My guess is probably no more than $2 billion.”
O’Neill, who was asked last year by British Prime Minister David Cameron to take an economist’s view of the issue, said earlier this month that philanthropists and governments should create a new fund to support drug research. In his first assessment of the threat, O’Neill estimated that so-called anti-microbial resistance (AMR) could kill an extra 10 million people a year and cost up to $100 trillion by 2050 if it was not brought under control.
The UK Review on Antimicrobial Resistance has published its second report, outlining specific steps for action to tackle the rise of drug-resistant infections worldwide. The report says that while mounting concern about the rise of antimicrobial resistance is prompting an increase in infectious disease research, a lack of funding means it is difficult to take ideas forward and companies are deterred from entering the field.
“I am calling on international funders, philanthropic or governmental, to allocate money to a fund that can support blue sky science and incubate ideas that are more mature,” said Jim O’Neill, chair of the review, launching the report. Such a targeted fund would support research needed to pave the way for new drugs, for alternatives to antibiotics, and for new diagnostics to make sure the right drugs are used. It could reverse the brain drain to research areas that are currently better-paid and held in higher academic esteem, such as cancer, diabetes and dementia.
The UK government set up the review in July 2014. The first report, published in December, scoped the problem, concluding that unless action is taken to address this huge global problem, it could cost the world at least an additional 10 million lives a year by 2050, more than the number of people who currently die from cancer each year. The second report says much innovative thinking is happening in infectious disease research at the moment. But lack of funding means that while people, machines and laboratories are ready to tackle the next challenges, they are unable to do so. It also deters new entrants to the field. Without new doctors and scientists in academia, hospitals and drug companies, the ability to innovate will decrease just at the time it needs to reach its peak.
“In researching our latest report, we found no shortage of ideas and promising new technologies but progress is too slow due to lack of investment, and much of the workforce is edging towards retirement,” said O’Neill. The review team is currently investigating market incentives in preparation for its next report in the Spring. Antibiotics generate low or even negative returns on investment meaning new mechanisms are needed to pull companies back into the field.